182 related articles for article (PubMed ID: 37526847)
1. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Frameworks for Gene and Cell Therapies in Japan.
Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
[TBL] [Abstract][Full Text] [Related]
3. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
Fujita Y; Kawamoto A
Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
[TBL] [Abstract][Full Text] [Related]
4. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
5. Regulatory perspectives of Japan.
Kusakabe T
Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
[TBL] [Abstract][Full Text] [Related]
6. [Current status of the regulation and development of cell therapy products in Japan].
Igarashi Y; Sato Y
Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
[TBL] [Abstract][Full Text] [Related]
7. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
Sato Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
[TBL] [Abstract][Full Text] [Related]
8. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
Inokuma Y
Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
[TBL] [Abstract][Full Text] [Related]
10. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
11. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
Okada K; Sato Y; Sugiyama D; Sawa Y
Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
[TBL] [Abstract][Full Text] [Related]
12. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.
Nagai S; Sugiyama D
Clin Ther; 2019 Jan; 41(1):174-184.e3. PubMed ID: 30528048
[TBL] [Abstract][Full Text] [Related]
13. First Approval of Regenerative Medical Products under the PMD Act in Japan.
Konishi A; Sakushima K; Isobe S; Sato D
Cell Stem Cell; 2016 Apr; 18(4):434-5. PubMed ID: 27058934
[No Abstract] [Full Text] [Related]
14. Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine.
Tobita M; Konomi K; Torashima Y; Kimura K; Taoka M; Kaminota M
Regen Ther; 2016 Jun; 4():78-81. PubMed ID: 31245489
[TBL] [Abstract][Full Text] [Related]
15. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
Okada K; Miyata T; Sawa Y
Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
Jokura Y; Yano K; Yamato M
J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
[TBL] [Abstract][Full Text] [Related]
18. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
Takashima K; Morrison M; Minari J
Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
[TBL] [Abstract][Full Text] [Related]
19. Update on Regulation of Regenerative Medicine in Taiwan.
Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
[TBL] [Abstract][Full Text] [Related]
20. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
Viswanathan S; Bubela T
Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
